Patents Assigned to Rorer Pharmaceutical Corporation
  • Patent number: 5086069
    Abstract: Disclosed are novel peptide and pseudopeptide derivatives and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.
    Type: Grant
    Filed: February 5, 1990
    Date of Patent: February 4, 1992
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Scott I. Klein, Bruce F. Molino
  • Patent number: 5026709
    Abstract: A method for the preparation of a sustained release pharmaceutical composition comprising forming a fluidized ring of said particles and contacting said particles maintained suspended in said ring with a liquid composition containing a pharmaceutically active material and an alkali-soluble material.
    Type: Grant
    Filed: June 7, 1988
    Date of Patent: June 25, 1991
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Richard J. Harwood, Gunvant N. Mehta, Ramesh C. Jhawar, Liang-Lii Huang, Wayne M. Grim, Shun P. Li
  • Patent number: 4977162
    Abstract: This invention relates to certain quinolinyl-chromone compounds and their use as valuable pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: December 11, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Fu-Chih Huang, Henry F. Campbell, Keith S. Learn, Robert A. Galemmo, Jr.
  • Patent number: 4977246
    Abstract: Disclosed is a method of recovery of antihemophilic factor (AHF) from human plasma by precipitation with citric acid, sodium citrate, or potassium citrate.
    Type: Grant
    Filed: June 6, 1989
    Date of Patent: December 11, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Ted C. K. Lee, Michael E. Hrinda
  • Patent number: 4959485
    Abstract: This invention is directed to certain dibenzofurancarboxamides and their use as 5HT.sub.3 antagonists having unique CNS, anti-emetic and gastric prokinetic activity void of any significant D.sub.2 receptor binding properties. This invention also describes novel processes necessary for their preparation.
    Type: Grant
    Filed: May 15, 1989
    Date of Patent: September 25, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Raymond D. Youssefyeh, Henry F. Campbell, Donald E. Kuhla
  • Patent number: 4954494
    Abstract: This invention relates to pyridyl-pyrazolinone compounds of the formula ##STR1## uses of said compounds as cardiotonic agents including methods for increasing cardia contractility and the treatment of congestive heart failure, pharmaceutical compositions including the same and methods for the preparation thereof.
    Type: Grant
    Filed: January 30, 1989
    Date of Patent: September 4, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Donald E. Kuhla, Henry F. Campbell, William L. Studt, William C. Faith
  • Patent number: 4952562
    Abstract: Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.
    Type: Grant
    Filed: September 29, 1989
    Date of Patent: August 28, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Scott I. Klein, Bruce F. Molino, Mark Czekaj, Charles J. Gardner, Jeffrey C. Pelletier
  • Patent number: 4948582
    Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
    Type: Grant
    Filed: May 11, 1989
    Date of Patent: August 14, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: John T. Suh, Robert G. Pendleton, Charles E. Pendley, II, Kin T. Yu, Paul R. Menard, Alain B. Schreiber
  • Patent number: 4946860
    Abstract: Disclosed are novel benzothiopyranyl derivatives as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula: ##STR1## their corresponding dihydroxy acids, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 3, 1989
    Date of Patent: August 7, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Robert L. Morris, Jeffrey N. Barton
  • Patent number: 4944829
    Abstract: A wrapper to be wrapped around a stack of disc-like tablets includes a portion carrying a layer of heat-activatable adhesive, which is activated just prior to wrapping the wrapper around the stack to secure it in position on the stack. The heat activation is provided by a short, hot blast of air directed onto a surface of the wrapper opposite that on which the heat-activatable layer is located, whereby the applied heat must travel through a portion of the wrapper to reach the adhesive layer and activate it. The air blast is heated by heaters which include elongated heat exchangers having rectangular grooves or slots extending along the length of their outer surfaces, through which grooves the air blast is constrained to travel for efficient, rapid heating.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: July 31, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Kenneth A. Tuttle, James Corrado
  • Patent number: 4939143
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: September 25, 1989
    Date of Patent: July 3, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: John R. Regan, Joseph G. Bruno, Kent W. Neuenschwander
  • Patent number: 4935511
    Abstract: This invention relates to benzoxazine and benzoxazepine carboxamide compounds which exhibit 5-HT.sub.3 antagonist properties including CNS, anti-emetic and gastric prokinetic activity and which are void of any significant D.sub.2 receptor binding affinity. This invention also relates to pharmaceutical compositions and methods for the treatment of gastrointestinal and mental disorders using said compounds.
    Type: Grant
    Filed: September 26, 1989
    Date of Patent: June 19, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Raymond D. Youssefyeh, Jeffrey C. Pelletier, Henry F. Campbell
  • Patent number: 4933445
    Abstract: This invention relates to heteroazabenzo-bicyclic substituted carboxamide compounds of the formula: ##STR1## where W is O, S or NR.sub.5 andZ is ##STR2## 3-quinuclidine, 4-quinuclidine,4-(1-azabicyclo[3.3.1]nonane),3-(9-methylazabicyclo[3.3.1]nonane),7-(3-oxo-9-methylazabicyclo[3.3.1]nonane) or4-[3-methoxy-1-(3-[4-fluorophenoxy[propyl)piperidine];which exhibit 5-HT.sub.3 antagonist properties including CNS, anti-emetic and gastric prokinetic activity. This invention further relates to pharmaceutical compositions and methods for the treatment of the above disorders.
    Type: Grant
    Filed: November 29, 1988
    Date of Patent: June 12, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Jeffrey C. Pelletier, Raymond D. Youssefyeh, Henry F. Campbell
  • Patent number: 4924010
    Abstract: Certain specific substituted 9-N-(1-azabicycolo-[2.2.2.]octan-3-yl)carboxamido-2,3,4,5-tetrahydro-1-ben zoxepins and their valuable use as 5-HT.sub.3 antagonists having CNS and gastric prokinetic activity and void of any significant D.sub.2 receptor binding properties are disclosed. Methods for their preparation also are described.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: May 8, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Raymond Youssefyeh, Scott I. Klein, Henry F. Campbell, Donald E. Kuhla
  • Patent number: 4906629
    Abstract: This invention relates to substituted pyridooxazinone and naphtheridone pyridazinone and pyrazolone compounds which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: March 6, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Alfred P. Spada, William L. Studt, Henry F. Campbell, Donald E. Kuhla, Thomas Tucker
  • Patent number: 4906630
    Abstract: A method for increasing cardiotonic contractility in humans or other animals using a class of benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds and pharmaceutical compositions including the same.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: March 6, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: William L. Studt, William C. Faith, Bruce F. Molino
  • Patent number: 4904692
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: December 12, 1988
    Date of Patent: February 27, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: John R. Regan, Josehp G. Bruno, Kent W. Neuenschwander, Donald E. Kuhla
  • Patent number: 4904691
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids and esters derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: March 10, 1989
    Date of Patent: February 27, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Kent W. Neuenschwander, Anthony C. Scotese
  • Patent number: 4892884
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: December 5, 1988
    Date of Patent: January 9, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Kent W. Neuenschwander, Anthony C. Scotese
  • Patent number: 4889868
    Abstract: This invention relates to chemical compounds which possess valuable therapeutic activity particularly as lipoxygenase and phospholipase C inhibitors and as platelet-activating factor receptor antagonists. The compounds posses anti-inflammatory anti-asthmatic and anti-allergic properties and are additionally useful for the treatment of myocardial infarctions.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: December 26, 1989
    Assignee: Rorer Pharmaceutical Corporation
    Inventor: Fu-chih Huang